ISTH Congress Abstracts

Official abstracts site for the ISTH Congress

MENU 
  • Home
  • Congress Archive
    • ISTH 2021 Congress
    • ISTH 2020 Congress
  • Resources
  • Search

Venous Thromboembolism in Patients with Renal Transplantation

D. Poli1, L. Migliaccio2, E. Antonucci2, L. Biancone3, G. Ghigliotti4, G. La Manna5, A. Ranghino6, P. Rigotti7, S. Tentori8, M. Zanazzi2, G. Palareti2

1Azienda Ospedaliera Universitaria Careggi, Firenze, Italy, 2Fondazione Arianna Anticoagulazione, Bologna, Italy, 3Università di Torino, Torino, Italy, 4Università di Genova, Genova, Italy, 5Università di Bologna, Bologna, Italy, 6Ospedali Riuniti di Ancona, Ancona, Italy, 7Università di Padova, Padova, Italy, 8Ospedale San Raffaele, Milano, Italy

Abstract Number: PB2372

Meeting: ISTH 2020 Congress

Theme: Venous Thromboembolism and Cardioembolism » VTE Prophylaxis

Background: Scant data are available about the characteristics and optimal treatment of the episode of venous thromboembolism (VTE) occurring in renal transplant (RT) recipients.

Aims: Our study was undertaken to evaluate the characteristics of VTE in RT patients, the type of treatment used in clinical practice and the risk of recurrent VTE.

Methods: We performed a multicentric retrospective observational study among 7 Italian centers. Data were collected in a web based clinical report form with the use of REDCAP system.

Results: 112 patients who received renal transplantation (74 males 64%) and who developed a first episode of VTE after transplantation. Median age (range) at transplantation was 57 (22-76) years. Median time of VTE recurrence from RT was 6 (0.1-213) months; 783% of patients received RT from deceased donor; 10 patients (9.0%) ha kidney and pancreas transplantation. Characteristics of site and type of VTE and treatment of VTE are reported in table 1. During follow-up 84/112 patients stopped anticoagulant treatment. Among them 25 (30%) had recurrent VTE episodes.

Conclusions: We confirm the low rate of pulmonary embolism in RT patients with respect to general population. Instead, RT patients showed a high rate of recurrence accordingly with previous findings.

Patients 112
DVT 90(85.7%)
EP 4 (3.8%)
DVT/EP 11 (10.4%)
Unprovoked 78 (73.5%)
Secondary to transient risk factors 28 (26.5%)
LMWH/warfarin 55 (52.4%)
Warfarin 41 (39.0%
DOACs 9 (8.6%)
Median (range) duration of treatment, months 6 (1-144)

[Site and type of VTE, treatment of VTE]

To cite this abstract in AMA style:

Poli D, Migliaccio L, Antonucci E, Biancone L, Ghigliotti G, La Manna G, Ranghino A, Rigotti P, Tentori S, Zanazzi M, Palareti G. Venous Thromboembolism in Patients with Renal Transplantation [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1). https://abstracts.isth.org/abstract/venous-thromboembolism-in-patients-with-renal-transplantation/. Accessed May 16, 2022.

« Back to ISTH 2020 Congress

ISTH Congress Abstracts - https://abstracts.isth.org/abstract/venous-thromboembolism-in-patients-with-renal-transplantation/

Simple Search

Supported By:

Bristol Myers Squibb and Pfizer

ISTH 2021 Congress site

Visit the official web site for the ISTH 2021 Virtual Congress »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2022 John Wiley & Sons, Inc. All Rights Reserved.
Wiley